Scinai Immunotherapeutics Ltd.
corporate_fare Company Profile
Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 18 items for SCNI at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-08, rated 7/10. Across its 18 most recent items scored 7 or higher, the top rating is 10/10, with 15 rated 8 or above. Recent SEC coverage for SCNI spans 6-K, 424B3, F-3, 20-F.
Recent high-impact activity:
- Scinai Ends PC111 Partnership, Pivots to NanoAb Platform and CDMO Growth
- Scinai's H1 2026: $3.1M in CDMO Orders, $650K in U.S. Program Advances, and a $6.4M Non-Cash Gain
- Scinai Moves to Regain Nasdaq Compliance with 1-for-10 ADS Ratio Change
- Shareholders Approve Massive Increase in Authorized Shares, Enabling Future Capital Raises
- Scinai Reports Q1 Results, Completes Strategic CDMO Acquisition with $6.2M Bargain Gain
Financial Snapshot
Dilution Risk
Low riskFiling-implied dilution signals for SCNI, detected from its recent SEC filings · based on capital-structure filings through 2026-05-19.
Resale Registration Finalized · Significant Potential Dilution
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
SCNI files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.